Management of hyperuricemia in gout: focus on febuxostat.
about
Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 1: Epidemiology and pathophysiology.Painless nodules over joints with ulcerationEfficacy and safety of febuxostat in patients with hyperuricemia and gout.Allopurinol and oxypurinol promote osteoblast differentiation and increase bone formation.Rhazes viewpoints about causes, diagnosis, treatment and prognosis of goutEffect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals.New advances in the treatment of gout: review of pegloticaseParadoxical and bidirectional drug effects.Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment.Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 2: clinical features, diagnosis and differential diagnostics.Development of 2-(Substituted Benzylamino)-4-Methyl-1, 3-Thiazole-5-Carboxylic Acid Derivatives as Xanthine Oxidase Inhibitors and Free Radical Scavengers.2-Benzamido-4-methylthiazole-5-carboxylic Acid Derivatives as Potential Xanthine Oxidase Inhibitors and Free Radical Scavengers.Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience.
P2860
Q30235586-3536EBA1-8E85-4098-9582-EBDA735A89B0Q35519415-3BE3DEE9-7269-44C3-AA96-3A5FB538EDB6Q36059557-C1D6884C-D213-45BD-BDAA-776E1406B51AQ36791027-D212E110-B4B2-46A7-9D0C-4B9B2C2D9EDFQ37020794-28E08F5F-4DB9-4F65-A2C5-C9A264030F5CQ37320504-69247019-EF36-45FF-A7A7-4298052FAA7EQ37434571-B0AB4FA0-2B5A-47A2-8EE7-39C6B2395F58Q37815379-6A9D4C07-3F2C-4B56-B1A6-C87C28531B90Q37978338-41DCA32D-42FD-407B-BB01-416BB6F9C761Q38936565-6E786A6A-B8C3-4918-B17D-0AE8E5D73D70Q39148778-46827CC4-62D2-4582-AE40-BF302EA4DA52Q40314317-873E7C9E-615C-4757-A7A9-7495CEE8118FQ46426129-317281F9-9B0C-4AA8-965F-9F6BC8563E0CQ48275640-145D2A51-F40F-417B-B49A-7299AF252068
P2860
Management of hyperuricemia in gout: focus on febuxostat.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Management of hyperuricemia in gout: focus on febuxostat.
@ast
Management of hyperuricemia in gout: focus on febuxostat.
@en
type
label
Management of hyperuricemia in gout: focus on febuxostat.
@ast
Management of hyperuricemia in gout: focus on febuxostat.
@en
prefLabel
Management of hyperuricemia in gout: focus on febuxostat.
@ast
Management of hyperuricemia in gout: focus on febuxostat.
@en
P2860
P921
P356
P1476
Management of hyperuricemia in gout: focus on febuxostat
@en
P2093
Mattheus K Reinders
P2860
P356
10.2147/CIA.S5476
P407
P50
P577
2010-02-02T00:00:00Z